PSLRA

Iovance Biotherapeutics to Present at Upcoming Conferences

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Cervical cancer, PSLRA, Perception, SAN, TIL, Food, Risk, Safety, Life, Patient, Annual report, Food and Drug Administration, Security (finance), Cancer, Clinical trial, FDA, BLA, Pharmaceutical industry, Iovance Biotherapeutics

We are pioneering a transformational approach to cure cancer by harnessing the human immune systems ability to recognize and destroy diverse cancer cells in each patient.

Key Points: 
  • We are pioneering a transformational approach to cure cancer by harnessing the human immune systems ability to recognize and destroy diverse cancer cells in each patient.
  • Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer.
  • The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.
  • Certain matters discussed in this press release are forward-looking statements of Iovance Biotherapeutics, Inc. (hereinafter referred to as the Company, we, us, or our) within the meaning of the Private Securities Litigation Reform Act of 1995 (the PSLRA).

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Retrieved on: 
Friday, November 18, 2022
COVID-19, Cervical cancer, PSLRA, Perception, SAN, TIL, Food, IND, Risk, Safety, Life, Regenerative medicine, Melanoma, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BRAF, Food and Drug Administration, Annual report, Webcast, Security (finance), Cancer, Clinical trial, FDA, BLA, Pharmaceutical industry, Iovance Biotherapeutics

Iovance will address these FDA comments promptly and will now complete its rolling BLA submission during the first quarter of 2023.

Key Points: 
  • Iovance will address these FDA comments promptly and will now complete its rolling BLA submission during the first quarter of 2023.
  • The FDA has provided recent valuable feedback to the IND application and remains supportive during the rolling BLA submission process.
  • The FDA previously granted a regenerative medicine advanced therapy ( RMAT ) designation for lifileucel in advanced melanoma.
  • The BLA submission for lifileucel is supported by positive clinical data from the C-144-01 clinical trial in patients with advanced melanoma.

Cecil Bank Announces Termination of Regulatory Written Agreement

Retrieved on: 
Friday, November 18, 2022
Federal Reserve Bank, PSLRA, Bank, Plan, OTC, State, Equal housing lender, FDIC, Rising Sun, Sun, Sale, Writing, Financial regulation, Security (finance)

ELKTON, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cecil Bancorp, Inc. ("Company") (OTC: CECL) announced that its wholly-owned banking subsidiary, Cecil Bank (the "Bank"), received notification from the Federal Reserve Bank of Richmond and State of Maryland Commissioner of Financial Regulation ("Supervisory Authorities") that the Written Agreement the Bank had been operating under since June 29, 2010, was terminated effective Nov. 3, 2022.

Key Points: 
  • ELKTON, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cecil Bancorp, Inc. ("Company") (OTC: CECL) announced that its wholly-owned banking subsidiary, Cecil Bank (the "Bank"), received notification from the Federal Reserve Bank of Richmond and State of Maryland Commissioner of Financial Regulation ("Supervisory Authorities") that the Written Agreement the Bank had been operating under since June 29, 2010, was terminated effective Nov. 3, 2022.
  • "Termination of this regulatory agreement is a fitting end to 2022 for Cecil Bank," said William H. Cole, Chair of the Bank's Board.
  • For the first nine months of 2022, Cecil Bank recorded net income of approximately $10.3 million.Cecil Bank ended the September quarter with assets of approximately $242.5 million and total equity of $28.0 million.
  • Cecil Bank is a state-chartered community bank established in October 1959 and headquartered in Elkton, Maryland.

GOGL – Third Quarter 2022 Results

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, International Maritime Organization, PSLRA, Union, Disclosure, Insurance, Social, Transport, Annual report, Crew management, Pandemic, Epidemic, Accident, Security (finance), Piracy, Aggression, Biophysical environment, Investment, Public expenditure, Acquisition, Risk management, Euro

The Company is taking advantage of the safe harbor provisions of the PSLRA and is including this cautionary statement in connection therewith.

Key Points: 
  • The Company is taking advantage of the safe harbor provisions of the PSLRA and is including this cautionary statement in connection therewith.
  • The Company cautions that assumptions, expectations, projections, intentions and beliefs about future events may and often do vary from actual results and the differences can be material.
  • These forward-looking statements are not guarantees of the Companys future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements.
  • This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Unrivaled Brands Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
PSLRA, Communication, Insurance, Stick, OTCQX, Annual report, Maintenance, An Act to exempt a particular class of securities from the Securities and Exchange Act, Security (finance), Tax, Risk, Transformers (toy line), Depreciation

SANTA ANA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQX: UNRV) ("Unrivaled" or the "Company"), a multi-state vertically integrated cannabis company with operations in California and Oregon,today reported its third quarter 2022 financial results for the quarter ended September 30, 2022.

Key Points: 
  • SANTA ANA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQX: UNRV) ("Unrivaled" or the "Company"), a multi-state vertically integrated cannabis company with operations in California and Oregon,today reported its third quarter 2022 financial results for the quarter ended September 30, 2022.
  • Those increases were partially offset by decreases in third quarter 2022 of the following items: taxes, licensing and permitting decreased by $0.51 million and stock compensation expenses decreased by $1.14 million.
  • Unrivaled Brands is a multi-state vertically integrated company focused on the cannabis sector with operations in California and Oregon.
  • In California, Unrivaled Brands operates three dispensaries with direct-to-consumer delivery, two cultivation facilities, and several leading company-owned brands.

United Rentals Announces Pricing of Private Offering of $1.5 Billion of 6.00% Senior Secured Notes due 2029

Retrieved on: 
Tuesday, November 15, 2022
Architecture, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Renting, Sale, URI, URNA, Senior, Russell, News, NYSE, Insurance, Acquisition, Security (finance), Person, Report, PSLRA, Standard, SEC Rule 144A, Regulation, Tax, Property management, United Rentals, Note

United Rentals, Inc. (NYSE: URI) (URI) today announced that its subsidiary, United Rentals (North America), Inc. (URNA), has priced an offering of $1.5 billion principal amount of 6.00% Senior Secured Notes due 2029 (the Notes) in a private offering.

Key Points: 
  • United Rentals, Inc. (NYSE: URI) (URI) today announced that its subsidiary, United Rentals (North America), Inc. (URNA), has priced an offering of $1.5 billion principal amount of 6.00% Senior Secured Notes due 2029 (the Notes) in a private offering.
  • URNAs obligations under the Notes will be guaranteed on a first-priority senior secured basis by URI and certain of URNAs domestic subsidiaries.
  • URNA is offering the Notes (and the related guarantees) pursuant to an exemption under the Securities Act of 1933, as amended (the Securities Act).
  • No assurance can be made that the offering of Notes will be consummated on its proposed terms or at all.

United Rentals Announces Proposed Private Offering of $1.5 Billion of Senior Secured Notes due 2029

Retrieved on: 
Tuesday, November 15, 2022
Architecture, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Renting, Sale, URI, URNA, Senior, Russell, News, NYSE, Insurance, Acquisition, Security (finance), Person, Report, PSLRA, Standard, SEC Rule 144A, Regulation, Tax, Property management, United Rentals, Note

United Rentals, Inc. (NYSE: URI) (URI) today announced that its subsidiary, United Rentals (North America), Inc. (URNA), is offering $1.5 billion principal amount of Senior Secured Notes due 2029 (the Notes) in a private offering.

Key Points: 
  • United Rentals, Inc. (NYSE: URI) (URI) today announced that its subsidiary, United Rentals (North America), Inc. (URNA), is offering $1.5 billion principal amount of Senior Secured Notes due 2029 (the Notes) in a private offering.
  • URNAs obligations under the Notes will be guaranteed on a first-priority senior secured basis by URI and certain of URNAs domestic subsidiaries.
  • URNA is offering the Notes (and the related guarantees) pursuant to an exemption under the Securities Act of 1933, as amended (the Securities Act).
  • No assurance can be made that the offering of Notes will be consummated on its proposed terms or at all.

United Rentals to Acquire Ahern Rentals for $2 Billion

Retrieved on: 
Monday, November 14, 2022
Architecture, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Building Systems, Sale, Communication, GAAP, Sullivan & Cromwell, Russell, Prospectus, Insurance, Acquisition, Security (finance), Report, PSLRA, Standard, EBITDA, Oliver Cromwell, Tax, Property management, United Rentals

A presentation about the transaction is available in the Investor Relations section of the United Rentals website.

Key Points: 
  • A presentation about the transaction is available in the Investor Relations section of the United Rentals website.
  • United Rentals, Inc. is the largest equipment rental company in the world.
  • United Rentals is a member of the Standard & Poors 500 Index, the Barrons 400 Index and the Russell 3000 Index and is headquartered in Stamford, Conn. Additional information about United Rentals is available at unitedrentals.com .
  • Ahern Rentals adjusted EBITDA is a non-GAAP financial measure as defined under the rules of the Securities and Exchange Commission.

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Hospital, Private Securities Litigation Reform Act, Intellectual property, Marketing, Investment, NYSE, ISR, Seed, IsoRay, Webcast, Research, Travel, Health, Total, COVID-19, Cancer, SEC, ISO, News, Compliance, Brain, Time, D, Physician, Patient, Growth, D&O, PSLRA, FDA, Video game, Pharmaceutical industry

Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.

Key Points: 
  • Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.
  • The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders.
  • Revenue for the first quarter of fiscal 2023 decreased 33% to $1.72 million versus $2.56 million in the prior year comparable period.
  • Prostate brachytherapy represented 68% of total revenue for the first quarter of fiscal 2023 compared to 77% in the prior year comparable period.

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Operating cost, Horizon Therapeutics, Private Securities Litigation Reform Act, PIN, Intellectual property, PCR, U.S. Securities and Exchange Commission, Patent, Therapy, Prescription, Growth hormone, Research, Risk, Laboratory, Rationalization, Sale, COVID-19 testing, COVID-19, Legislation, OPKO Health, Modex, COVID, NASDAQ, International, Time, Pharmaceutical Benefits Scheme, Patient, EU, Growth, Security (finance), BRL, PSLRA, Health, Acquisition, FDA, Income, Video game, Pharmaceutical industry, Pfizer

During the third quarter of 2022, OPKO received gross profit share and royalty payments from Pfizer related to sales of NGENLA.

Key Points: 
  • During the third quarter of 2022, OPKO received gross profit share and royalty payments from Pfizer related to sales of NGENLA.
  • There were several significant events that positively impacted third quarter 2021 results, and should be considered when comparing those results to 2022.
  • BRL processed approximately 0.2 million COVID-19 PCR tests in the third quarter of 2022 versus 2.2 million tests in the third quarter of 2021.
  • Operating loss for the third quarter of 2022 was $87.8 million compared with operating income of $37.8 million for the 2021 quarter.